Artificial intelligence-derived risk score for mortality in secondary mitral regurgitation treated by transcatheter edge-to-edge repair: the EuroSMR risk score
Jörg Hausleiter,Mark Lachmann,Lukas Stolz,Francesco Bedogni,Antonio P Rubbio,Rodrigo Estévez-Loureiro,Sergio Raposeiras-Roubin,Peter Boekstegers,Nicole Karam,Volker Rudolph,Thomas Stocker,Mathias Orban,Daniel Braun,Michael Näbauer,Steffen Massberg,Aniela Popescu,Tobias Ruf,Ralph Stephan von Bardeleben,Christos Iliadis,Roman Pfister,Stephan Baldus,Christian Besler,Tobias Kister,Karl Kresoja,Philipp Lurz,Holger Thiele,Benedikt Koell,Niklas Schofer,Daniel Kalbacher,Michael Neuss,Christian Butter,Karl-Ludwig Laugwitz,Teresa Trenkwalder,Eroion Xhepa,Michael Joner,Hazem Omran,Vera Fortmeier,Muhammed Gerçek,Harald Beucher,Thomas Schmitz,Alexander Bufe,Jürgen Rothe,Melchior Seyfarth,Tobias Schmidt,Christian Frerker,Dennis Rottländer,Patrick Horn,Maximilian Spieker,Elric Zweck,Mohammad Kassar,Fabien Praz,Stephan Windecker,Tania Puscas,Marianna Adamo,Laura Lupi,Marco Metra,Emmanuel Villa,Giuseppe Biondi Zoccai,Corrado Tamburino,Carmelo Grasso,Fausto Catriota,Luca Testa,Maurizio Tusa,Cosmo Godino,Michele Galasso,Matteo Montorfano,Eustachio Agricola,Paolo Denti,Federico De Marco,Giuseppe Tarantini,Giulia Masiero,Gabriele Crimi,Andrea Raffaele Munafò,Christina Giannini,Anna Petronio,Stefano Pidello,Paolo Boretto,Antonio Montefusco,Simone Frea,Filippo Angelini,Pier Paolo Bocchino,Francesco De Felice,Rodolfo Citro,Berenice Caneiro-Queija,Xavier Freixa,Ander Regueiro,Laura Sanchís,Manel Sabaté,Dabit Arzamendi,Lluís Asmarats,Estefanía Fernández Peregrina,Tomas Benito-González,Felipe Fernández-Vázquez,Isaac Pascual,Pablo Avanzas,Luis Nombela-Franco,Gabriela Tirado-Conte,Eduardo Pozo,Antonio Portolés-Hernández,Vanessa Moñivas Palomero,Francisco Sampaio,Bruno Melica,Josep Rodes-Cabau,Jean-Michel Paradis,Alberto Alperi,Mony Shuvy,Dan Haberman,the EuroSMR Investigators
DOI: https://doi.org/10.1093/eurheartj/ehad871
IF: 39.3
2024-01-22
European Heart Journal
Abstract:Risk stratification for mitral valve transcatheter edge-to-edge repair (M-TEER) is paramount in the decision-making process to appropriately select patients with severe secondary mitral regurgitation (SMR). This study sought to develop and validate an artificial intelligence-derived risk score (EuroSMR score) to predict 1-year outcomes (survival or survival + clinical improvement) in patients with SMR undergoing M-TEER. An artificial intelligence-derived risk score was developed from the EuroSMR cohort (4172 and 428 patients treated with M-TEER in the derivation and validation cohorts, respectively). The EuroSMR score was validated and compared with established risk models. The EuroSMR risk score, which is based on 18 clinical, echocardiographic, laboratory, and medication parameters, allowed for an improved discrimination of surviving and non-surviving patients (hazard ratio 4.3, 95% confidence interval 3.7–5.0; P < .001), and outperformed established risk scores in the validation cohort. Prediction for 1-year mortality (area under the curve: 0.789, 95% confidence interval 0.737–0.842) ranged from 70%, including the identification of an extreme-risk population (2.6% of the entire cohort), which had a very high probability for not surviving beyond 1 year (hazard ratio 6.5, 95% confidence interval 3.0–14; P < .001). The top 5% of patients with the highest EuroSMR risk scores showed event rates of 72.7% for mortality and 83.2% for mortality or lack of clinical improvement at 1-year follow-up. The EuroSMR risk score may allow for improved prognostication in heart failure patients with severe SMR, who are considered for a M-TEER procedure. The score is expected to facilitate the shared decision-making process with heart team members and patients. The EuroSMR risk score. The EuroSMR risk score was developed from the extended EuroSMR registry, including a total of 4600 patients in the derivation (4172 patients) and validation (428 patients) cohorts. The artificial intelligence-based algorithm identified 18 risk parameters associated with 1-year survival after mitral valve transcatheter edge-to-edge repair. The application of the EuroSMR risk score performed similarly with respect to survival prediction in the derivation and validation cohorts. With an increasing EuroSMR risk score, the predicted probability for mortality with or without New York Heart Association class improvement is increasing. BMI, body mass index; COPD, chronic obstructive pulmonary disease; eGFR, estimated glomerular filtration rate; EROA, effective regurgitant orifice area; GDMT, guideline-directed medical therapy; LA, left atrial; LVEDV, left ventricular end-diastolic volume; LVEF, left ventricular ejection fraction; M-TEER, mitral valve transcatheter edge-to-edge repair; NT, proBNP, N-terminal pro-brain natriuretic peptide; NYHA, New York Heart Association; RA, right atrial; RV, right ventricular; SHAP, SHapley Additive exPlanations; sPAP, systolic pulmonary artery pressure; TAPSE, tricuspid annular plane systolic excursion; TR, tricuspid regurgitation.
cardiac & cardiovascular systems